Evidence map›Paper›PMID 37697209›Full record

ArticleVeterinary research communications2024

Antiviral mechanisms of sorafenib against foot-and-mouth disease virus via c-RAF and AKT/PI3K pathways.

Sirin Theerawatanasirikul, Varanya Lueangaramkul, Ploypailin Semkum, Porntippa Lekcharoensuk

Abstract read
PubMed Publisher
In one paragraph

Article in Veterinary research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sirin TheerawatanasirikulDepartment of Anatomy, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand. fvetsrth@ku.ac.th.ORCID http://orcid.org/0000-0002-6912-9764
Varanya LueangaramkulDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand.ORCID http://orcid.org/0009-0001-5953-976X
Ploypailin SemkumDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand.ORCID http://orcid.org/0000-0002-3279-7160
Porntippa LekcharoensukDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, 10900, Thailand. fvetptn@ku.ac.th.ORCID http://orcid.org/0000-0001-5595-3296
Kasetsart University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Foot-and-mouth disease virus (FMDV) is a highly contagious pathogen that poses a significant threat to the global livestock industry. However, specific antiviral treatments against FMDV are currently unavailable. This study aimed to evaluate the antiviral activity of anticancer drugs, including kinase and non-kinase inhibitors against FMDV replication in BHK-21 cells. Sorafenib, a multi-kinase inhibitor, demonstrated a significant dose-dependent reduction in FMDV replication. It exhibited a half maximal effective concentration (EC50) value of 2.46 µM at the pre-viral entry stage and 2.03 µM at the post-viral entry stage. Further intracellular assays revealed that sorafenib effectively decreased 3D

Indexed as

Foot-and-Mouth DiseaseFoot-and-Mouth Disease VirusAnimalsAntiviral AgentsCell LineMolecular Docking SimulationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSorafenibVirus ReplicationAntiviral AgentsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSorafenib3DpolAntiviral activityFoot-and-mouth disease virus (FMDV)Kinase inhibitorSorafenib

Identifiers

PMID37697209
OpenAlexW4386597823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.